Novo Combination Obesity Shot Meets Goal in Diabetes Trial

Summary
Novo Nordisk announced positive results from a Phase 3 trial for their experimental combination shot, CagriSema, in people with diabetes and obesity. This adds to the evidence for regulatory approval of the drug, which has already been submitted for approval in obesity. The results also pose a potential threat to Eli Lilly’s obesity drug, Zepbound, which has overtaken Novo’s Wegovy in sales.

Access Impact
The trial showed that CagriSema helped lower blood sugar and produce greater weight loss compared to Wegovy in people with diabetes and obesity. This could have pricing, reimbursement, and HTA implications for these drugs in the future, especially if CagriSema is approved for use in both obesity and diabetes. However, a head-to-head trial comparing CagriSema and Zepbound has yet to be completed, so the full impact remains to be seen.

Top-3 Domain Lens
Clinical Effectiveness
CagriSema has shown to be effective in lowering blood sugar and producing weight loss in people with diabetes and obesity, which could make it a promising treatment option in this population.

Cost-Effectiveness
The trial results for CagriSema showed a reduction in blood sugar and weight loss, which could potentially translate to cost savings for patients and healthcare systems in the long run.

Safety and Tolerability
CagriSema showed typical side effects of GLP-1-based weight loss therapies, such as gastrointestinal problems, but these side effects diminished over time.

Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug #RegulatoryAgency

CTA
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list

Source
source: https://www.biopharmadive.com/news/novo-cagrisema-diabetes-reimagine-study-results/811115/